{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132760","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.839918+00:00","generated_at":"2026-05-20T03:09:58.008179+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kymera reports positive Phase 1 data for oral STAT6 degrader KT-621; >90% STAT6 degradation at low doses","bullets":["SAD: >90% mean STAT6 degradation in blood at doses starting at 6.25 mg; ≥75 mg achieved complete degradation.","MAD: complete STAT6 degradation in blood and skin at doses ≥50 mg; safety undifferentiated from placebo with no SAEs.","Th2 biomarkers: median TARC -37%, Eotaxin-3 -63% at Day 14, comparable or superior to dupilumab in healthy volunteers.","KT-621 well-tolerated: no TRAEs in >1 subject, no severe AEs, no discontinuations, no clinically relevant lab/ECG changes.","Next steps: Phase 1b AD data Q4 2025; Phase 2b AD start Q4 2025, asthma Q1 2026, enabling parallel Phase 3 readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132760","json":"https://secwatch.observer/filing/0001193125-25-132760.json","markdown":"https://secwatch.observer/filing/0001193125-25-132760.md","text":"https://secwatch.observer/filing/0001193125-25-132760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525132760/0001193125-25-132760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525132760/d57872d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:09:58.008179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}